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Abstract: Anticancer properties of tyrindoleninone and 6-bromoisatin from Dicathais orbita 
were tested against physiologically normal primary human granulosa cells (HGC) and 
reproductive cancer cell lines. Tyrindoleninone reduced cancer cell viability with IC50 
values of 39 µM (KGN; a tumour-derived granulosa cell line), 39 μM (JAr), and 156 μM  
(OVCAR-3), compared to 3516 μM in HGC. Apoptosis in HGC’s occurred after 4 h at  
391 µM tyrindoleninone compared to 20 µM in KGN cells. Differences in apoptosis 
between HGC and KGN cells were confirmed by TUNEL, with 66 and 31% apoptotic 
nuclei at 4 h in KGN and HGC, respectively. These marine compounds therefore have 
potential for development as treatments for female reproductive cancers. 
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1. Introduction 
Gynaecological cancers of the ovary, cervix and endometrial are less common than either lung or 
breast cancer in women, but the mortality rates are higher due to late diagnosis [1,2]. Ovarian cancer 
presents very few symptoms, yet is a rapidly growing aggressive cancer [3], with the highest incidence 
of mortality of all the gynaecological cancers, and a 5-year survival rate of 26% [4]. While the 
incidence of cervical cancer is decreasing in developed countries, it is still the second most common 
gynaecological cancer world-wide, with over half a million cases diagnosed each year [5]. Because 
women often present late with gynaecological cancers, treatments are often aggressive but fatalities 
still occur from relapse of the disease [6]. 
Nature has been an important source of novel anti-cancer drug leads over the past 25 years [7] with 
increasing numbers of new compounds sourced from the marine environment [8–13]. A recent 
economic analysis has estimated the value of anti-cancer drugs of marine origin at US $563 billion to 
5.69 trillion pending discovery, with up to 214 new compounds predicted to reach the market in the 
future [14]. The novel and diverse structures of marine compounds makes them a preferred source for 
new drug candidates [10,15] especially for multi-drug resistant carcinomas, such as ovarian   
cancer [6,16]. The drug Trabectedin (Yondelis
®; PharmaMar), isolated from the marine tunicate, 
Ecteinascidia turbinata, has a unique mode of action; it inhibits several transcription factors in vitro 
and in vivo [17,18] and has now been approved for the treatment of platinum-sensitive ovarian cancer 
and tumour soft tissue sarcoma [19]. A range of bioactive compounds with anticancer properties have 
also been isolated from molluscs [10,15,20,21]. Dolastatin-10, and 15, derived from the shell-less 
mollusc Dolabella auricularia [22], were reported to have anti-tumour activity against breast and liver 
cancer in phase I clinical trials [23]. In phase II trials, however Dolastatin-10 had minimal activity 
against breast and platinum-sensitive ovarian cancer [24,25]. Another bioactive compound Kahalalide F, 
isolated from the marine mollusc, Elysia rufescens [26], has shown anti-tumour activity in breast, 
hepatoma, melanoma and pancreatic carcinomas in phase I clinical trials [9,27]. A synthetic derivative 
PM02734 of Kahalalide F, induces apoptosis in lung cancer cell lines (H322 and A549), in vitro and 
in vivo and is currently undergoing phase II clinical trials [28]. The compound, ES-285–HCl originally 
isolated from the clam Spisula polynyma, has shown selective anticancer properties against several 
cancer cell lines in vitro and against solid hepatocellular, prostate and renal tumours in vivo [29]. 
The indole derivatives tyrindoleninone, tyrindolinone, 6-bromoisatin and 6,6′-dibromoindirubin, 
from the Muricidae family of marine gastropods, also have anti-cancer properties [30–32]. In vitro, 
these indole compounds inhibited cell growth in solid tumour cell lines from the colon and breast, and 
induced apoptosis and necrosis in T-cell lymphoma cells [30]. Tyrindoleninone in particular, is 
cytotoxic against the human lymphoma cell lines, U937 and Jurkat (IC50 = 3.9 μM; 1 μg/mL) in 
comparison to the untransformed, human, mononuclear cells (MNC) (IC50 = 195 μM; 50 μg/mL)  
in vitro [30,31]. In vivo studies in a rodent model for the prevention of colon cancer have also shown 
that crude extracts from the muricid, Dicathais orbita  (Muricidae, Gastropoda) containing these 
compounds are pro-apoptotic in cells of the distal colon in response to administration of the genotoxic 
agent, azoxymethane [32].  
The muricid family of whelks is the source of a homeopathic remedy “Murex purpurea”, 
recommended for the treatment of gynaecological disorders including cancer of the uterus [33,34], but Mar. Drugs 2012, 10  
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the remedy had little or no effect on cell proliferation across a range of cancer cell lines in vitro [30]. 
Only trace amounts of 6-bromoisatin were detected in the homeopathic remedy used in this study [30]. 
However, indirubin, a related compound is the active ingredient in the traditional Chinese medicine, 
“Danggui Luhui Wan”, used for treating leukaemia [35] and induces apoptosis in prostate and lung 
cancer [36]. Isatins and analogues of isatin also have anti-proliferative and anti-cancer properties  
in vitro [31,37]. 5- and 7-bromoisatin act by inhibiting micro-tubular formation in cancer cell lines  
in vitro [37]. Vine et al. [31] demonstrated that a range of isatins including 5 and 7-dibromoisatin 
selectively promoted apoptosis in the lymphoma cell lines U937 and Jurkat, by the activation of 
effector caspases-3 and -7.  
The brominated indoles isolated from Dicathais orbita have not been tested for efficacy against 
aggressive gynaecological cancers. We therefore aimed to determine if compounds from D. orbita 
could selectively target human female reproductive cancer cell lines without causing significant cell 
death to primary-derived human reproductive cells. There are a wide range of human reproductive 
cancer cell lines available, including the KGN granulosa tumour cell line, established in 2001 from a 
63-year old women with an invasive carcinoma [38], the OVCAR-3 cancer cell line, originally derived 
from an adenocarcinoma of the ovary [39], and the JAr choriocarcinoma cell line established from a 
trophoblastic tumour of the placenta [40]. Primary human reproductive granulosa cells (HGC) derived 
from women with normal reproductive physiology undergoing assisted reproductive technologies 
(ART) were used in this study as a direct comparison to the KGN granulosa tumour cell line. The 
cytotoxic mode of action in KGN and HGCs was examined by using membrane integrity assays (LDH 
release) to identify necrosis, and apoptosis was examined by measurement of DNA fragmentation 
(TUNEL) and enzyme activity (caspase-3/7). As no marine natural products appear to have been 
previously tested for cytotoxicity against human primary granulosa cells, this study also presents a new 
model for screening anticancer agents specifically for female reproductive cancers. 
2. Results and Discussion  
2.1. Compound Identification 
The previously reported compounds, tyrindoleninone and 6-bromisatin from the marine whelk   
D. orbita [32,41], were readily isolated and purified from a crude egg capsule extract (3.726 g). 
LC/MS of the purified fractions identified one major compound in fraction one (0.120 g) at tR 11.32 min 
which corresponded to the molecular mass of tyrindoleninone (ESI/MS insert m/z 255, 257 isotopes for 
bromine Br
79, Br
81; Figure 1A). The fragmented ion at m/z 240 correlated to the loss of a hydroxyl 
group (-H2O) from the tyrindoleninone compound. The second fraction (0.105 g) consisted of one 
major HPLC peak at tR 6.45 min which was confirmed to be 6-bromoisatin by the molecular mass on 
the ESI/MS (insert; m/z 224, 226 for Br
79, Br
81; Figure 1B). The major fragment ion at m/z 198 is due 
to the loss of CO.  
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Figure 1. LC/MS analysis of the two purified fractions extracted from the egg capsules of 
D. orbita. (A) The chromatogram from the Diode array at 300 + 600 nm shows the 
retention times (tR) and relative peak of the main indole compound in the first fraction at  
tR 11.32 min. This fraction was confirmed to be tyrindoleninone by the molecular mass 
(ESI/MS insert; m/z 255, 257). (B) The second purified fraction at tR 6.45 min corresponded 
to that of 6-bromoisatin by its molecular weight (ESI/MS insert; m/z 224, 226). 
 
2.2. Biological Activity of the D. orbita Compounds 
2.2.1. Cell Viability  
Selective inhibition of cancer cell lines is a major advantage for anticancer agents, as non specific 
cytotoxicity in primary cells can cause undesirable side effects preventing FDA drug approval [10,30]. 
The two D. orbita fractions were tested for their cytotoxicity against three reproductive cancer cells 
lines and primary-derived human reproductive granulosa cells (HGC) using the crystal violet and MTT 
assay. Tyrindoleninone (fraction one) was more active against the reproductive cancer lines than the 
HGC and inhibited the metabolic function of the cells (MTT assay) before cell death occurred (Crystal 
violet assay; Table 1). Tyrindoleninone selectively reduced the viability of all three reproductive 
cancer cell lines KGN (IC50 = 39 µM MTT and 156 µM Crystal violet), JAr (IC50 = 39 µM MTT and 
234 µM Crystal violet) and OVCAR-3 (IC50 = 156 µM MTT and 313 µM Crystal violet) at much 
lower concentrations than the corresponding primary cells (IC50 = 3516 µM MTT and >1953 µM 
Crystal violet) after just 4 h exposure (Table 1). After 24, 48 and 72 h treatment, tyrindoleninone was Mar. Drugs 2012, 10  
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significantly more cytotoxic towards all three reproductive cancer cell lines, with IC50 values 
approximately 10-fold lower than for the HGC (Table 1). Benkendorff et al. [30] showed a 50% 
reduction in the MCF-7 breast, CaCo2 colon and U937 lymphoma carcinoma cell viability after 4 h 
exposure to 391 µM tyrindoleninone in an impure extract compared to untransformed mononuclear 
cells. Another study predicted a 50% reduction in lymphoma cell viability after 1 h exposure to 4 µM 
tyrindoleninone [31]. Furthermore, Vine et al. [31] identified that tyrindoleninone was much less 
cytotoxic to untransformed human mononuclear cells with IC50 = 195 µM after 1 h exposure. The 
different inhibitory concentrations in the various studies is likely to be due to the relative purity of 
tyrindoleninone in the extract tested, as well as innate differences in the susceptibility of different cell 
lines. Furthermore, Vine et al. [31] noted that a contaminating plasticizer in their study may have 
increased the solubility and availability of tyrindoleninone to the cells. Cell types vary with regards to 
their metabolic rate and cell culture conditions (such as cell density and passage numbers) and this can 
also influence the outcome of an assay [42]. 
Table 1. Cytotoxicity of tyrindoleninone and 6-bromoisatin to primary-derived human 
reproductive granulosa cells (HGC), KGN, JAr and OVCAR-3 cells determined by the 
crystal violet (CV) and the MTT assays, and results are shown as IC50 the concentration 
that inhibited 50% of the cells. The values are mean of three independent assays (n = 3).  
n/t: not tested; >: concentration is greater than; <: concentration is less than. 
Cell Type  Time (h) 
IC50 (µM) 
Tyrindoleninone 6-Bromoisatin 
CV MTT  CV  MTT 
HGC 
4 
>1953  3516  >2232  >4464 
KGN 156  39  892  178 
JAr 234  39  223  223 
OVCAR-3 313  156  446  402 
HGC 
24 
>1953  1563  >2232  >4464 
KGN  156  78  223  446 
JAr  195  117  178  446 
OVCAR-3  352  234  268  446 
HGC 
48 
n/t  1563  n/t  1785 
KGN  n/t  20  n/t  22 
JAr  n/t  78  n/t  446 
OVCAR-3  n/t  31  n/t  89 
HGC 
72 
n/t  1563  n/t  2232 
KGN  n/t  <20  n/t  <22 
JAr n/t  n/t  n/t  n/t 
OVCAR-3 n/t  <20  n/t  <22 
6-Bromoisatin, while not as potent as tyrindoleninone, still significantly decreased cell numbers in 
all three reproductive cancer cell lines, whilst having only a minimal effect on HGC (Table 1). The JAr 
cell line was the most sensitive after shorter incubation periods, with cell numbers halved at 223 µM 
(Crystal violet and MTT assay) and 178 µM and 446 µM (Crystal violet and MTT assay) of   
6-bromoisatin after 4 and 24 h exposures respectively (IC50; Table 1). In comparison, the HGC Mar. Drugs 2012, 10  
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numbers were only reduced by >2232 µM 6-bromoisatin after 24 h exposure. After 48 and 72 h 
exposure to 6-bromoisatin the concentration that inhibited 50% of KGN and OVCAR-3 cell lines was 
much lower (22 µM 48 and 72 h KGN and 89 and 22 µM OVCAR-3) as determined by the MTT assay. 
Vine et al. [31] have demonstrated that a range of substituted isatins including 5 and 7-dibromoisatin 
are 10× more active against the lymphoma cell lines, U937 and Jurkat than 6-bromoisatin. Nevertheless, 
the results from this study and previous research on the anticancer properties of these marine 
compounds in particular tyrindoleninone, all support the specificity of these compounds towards 
rapidly dividing cancer cell lines over freshly isolated healthy human cells. 
2.2.2. Mode of Action Investigation: Apoptosis and Necrosis Assays 
Cell death by necrosis leads to the loss of cell membrane integrity and uncontrolled release of the 
cellular contents into the surrounding tissue causing inflammation [43] and as such is often considered 
a toxic process in comparison to apoptosis [44]. It therefore is an advantage to identify anticancer 
agents that specifically induce apoptosis as opposed to necrosis. After exposure of the granulosa cancer 
cells KGN, and primary HGC to tyrindoleninone and 6-bromoisatin, caspase-3 and -7 enzymes were 
activated at much lower concentrations than those required to cause disruption of membrane integrity, 
indicating cell death occurred predominately by apoptosis as opposed to necrosis. For example, a four 
hour exposure to 1953 µM (0.5 mg/mL) tyrindoleninone (Figure 2) was required to cause LDH release 
in both HGC and the corresponding KGN granulosa cell line, with more LDH being released by KGN 
(1612 ± 771) than primary HGC (876 ± 1084). This effect was more marked after a 24 h exposure, 
when lower concentrations (195 µM; 0.05 mg/mL) caused LDH release from KGN cells, as opposed to 
primary HGC (1953 µM; 0.5 mg/mL). In comparison, caspase-3 and -7 activity was noted in HGC 
after 4 h treatment with 391 µM (0.1 mg/mL) tyrindoleninone (p < 0.01; Figure 3A), whereas the 
corresponding granulosa cancer cell line, KGN, had significant increases in caspase-3 and -7 activity at 
20 µM (0.005 mg/mL; p < 0.001; Figure 3B). In fact, there was greater capsase-3 and -7 activity 
detected overall by the KGN cells than in the corresponding primary HGC in the presence of 
tyrindoleninone. Furthermore, there was a dose dependant decrease in KGN caspase activity as the 
concentration of tyrindoleninone increased, whereas there was a dose dependent increase for HGC 
(Figure 3B). Finally, necrosis was only detected in the JAr and OVCAR-3 cells after 4 h exposure to 
195 µM (0.05 mg/mL) and 391 µM (0.1 mg/mL) of tyrindoleninone respectively (Figure 2). 
In a similar manner to tyrindoleninone, 6-bromoisatin significantly affected the reproductive cancer 
cell lines at lower concentrations than the HGC (Figure 4). Necrosis, as indicated by LDH release, was 
only significantly increased after 4 and 24 h exposure to 2232 µM (0.5 mg/mL) of 6-bromoisatin in 
HGC. In comparison, LDH release significantly increased after exposure to 446 µM (0.1 mg/mL) in 
the KGN, JAr and OVCAR-3 cells lines (Figure 4). Like tyrindoleninone, caspase-3 and -7 activity 
was only detected in HGC after 4 h treatment with 0.1 mg/mL 6-bromoisatin (p < 0.001; Figure 3C).  
In comparison KGN cell apoptotic activity was significantly higher after 4 h treatment with 22 µM 
(0.005 mg/mL) of 6-bromoisatin (p < 0.001; Figure 3D). When KGN cells were treated with   
22–2232 µM (0.005–0.5 mg/mL) of 6-bromoisatin for 24 h, caspase-3 and 7 significantly decreased, in 
a dose-dependent manner (Figure 3D). Mar. Drugs 2012, 10  
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Figure 2. Effects of tyrindoleninone on LDH release in the primary-derived human 
reproductive granulosa (HGC), KGN, JAr and OVCAR-3 cells. After an initial 2 h (JAr) 
and 24 h (HGC, KGN and OVCAR-3) cell attachment period the cells (10,000 cells/well) 
were treated with tyrindoleninone for 4 and 24 h. LDH release was measured by 
fluorescence at 535EX/590EM. The results are mean for three separate repeat assays (n = 3;  
±1 SEM). Univariate analysis of variance with contrast (K Matrix) were conducted to 
compare the effects of the concentration of tyrindoleninone on LDH release against the  
1% DMSO control shown as 0 concentration at 4 and 24 h. The positive control represents 
lysis buffer (Promega). Significant difference between each treatment and the 1% DMSO 
control at 4 and 24 h are shown as p < 0.01 (**) and p < 0.001 (***). 
 
Other structurally similar indole and isatin compounds have also been shown to induce apoptosis by 
the activation of caspase-3 at low concentrations, in a range of cell lines in vitro [31,45,46]. For 
example 5,6,7-tribromoisatin activates caspase-3 and -7 at 8 µM (0.003 mg/mL) after 5 h in the Jurkat 
cell line [31]. Other research suggests that indoles and isatins inhibit cell proliferation and activate 
apoptosis by binding and inhibiting signalling of extracellular protein kinases (ERKs) [47]. As ERK Mar. Drugs 2012, 10  
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signalling pathways, such as the ERK/MARK phosphatase pathway, are essential in cell proliferation 
and survival [48] it only follows that an inhibition of ERK would suppress growth and induce 
apoptosis in the cells. 
Figure 3. Up-regulation of caspase-3 and 7 in the primary-derived human reproductive 
granulosa (HGC) and KGN cells after incubation with tyrindoleninone (A,  B) and   
6-bromoisatin (C, D). After an initial 24 h cell attachment period cells (10,000 cells/well) 
were treated with tyrindoleninone and 6-bromoisatin for 4 and 24 h. Caspase-3 and -7 
activity was measured at full light on an luminescence plate reader. The results are mean 
for three separate repeat assays (n = 3; ±1 SEM). The positive control represents exposure 
of cells to 1 µg/mL DNase I. Univariate analysis of variance with contrast (K Matrix) were 
conducted to compare the effects of each compound on caspase-3 and -7 activity against 
the 1% DMSO control shown as 0 concentration at 4 and 24 h. Significant difference 
between each treatment and the 1% DMSO control at 4 and 24 h are shown as   
p < 0.01 (**) and p < 0.001 (***). 
 Mar. Drugs 2012, 10  
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Figure 4. Effects of 6-bromoisatin on LDH release in the primary-derived human 
reproductive granulosa (HGC), KGN, JAr and OVCAR-3 cells. After an initial 2 (JAr)  
and 24 h (primary HGC, KGN and OVCAR-3) cell attachment period the cells   
(10,000 cells/well) were treated with 6-bromoisatin for 4 and 24 h. LDH release was 
measured by fluorescence at 535EX/590EM. The results are mean for three separate repeat 
assays (n = 3; ±1 SEM). Univariate analysis of variance with contrast (K Matrix) were 
conducted to compare the effects of the concentration of 6-bromoisatin on LDH release 
against the 1% DMSO control shown as 0 concentration at 4 and 24 h. The positive control 
represents a lysis buffer (Promega). Significant difference between each treatment and the 
1% DMSO control at 4 and 24 h are shown as p < 0.01 (**) and p < 0.001 (***). 
 
2.2.3. Confirmation of Apoptosis by TUNEL Staining 
To further assess whether the two D. orbita fractions containing the bioactive compounds 
tyrindoleninone and 6-bromoisatin induced cell death by apoptosis, the TUNEL assay was performed 
on the HGC and KGN cells. The DNase I treated HGC and KGN cells (positive controls) were 100% 
TUNEL stained (Figures 5 and 6), whereas the negative controls (absence of terminal deoxynecleotide Mar. Drugs 2012, 10  
 
 
73
transferase) were TUNEL negative. After 4 and 24 h incubation, 9 and 12% of untreated (DMSO 
control) HGC, and 10 and 8% of KGN cells were TUNEL labelled (Figures 5 and 6). 
Figure 5. TUNEL staining of primary-derived reproductive human granulosa cells (HGC) 
(A 1–4) and KGN granulosa tumor cell line (A 5–8) after 4 h treatment with D. orbita 
fraction 1 containing tyrindoleninone. The percentage of apoptotic cells after HGC (B) and 
KGN cells (C) after treatment with tyrindoleninone for 4 h and 24 h. The positive control 
represents 1 µg/mL DNase I (C1 and 5), for comparison with the 1% DMSO control   
(C2 and 6), 0.005 mg/mL (C3 and 7) and 0.05 mg/mL (C4 and 8) of tyrindoleninone. 
Photomicrographs were taken of four random microscope fields, and the number of 
TUNEL positive nuclei were calculated as a fraction of the total number of PI stained 
nuclei in each image. The average of the four fields was then calculated and the results of 
(A) and (B) are the mean ± 1 SEM of 3 repeat assays (n = 3). Univariate analysis of 
variance with contrast (K Matrix) were conducted to determine the percentage of apoptotic 
cells from total cells induced by tyrindoleninone against the 1% DMSO control shown as  
0 concentration at 4 and 24 h. Significant difference between each treatment and the   
1% DMSO control at 4 and 24 h shown as p < 0.01 (**) and p < 0.001 (***). (C) Pictures 
represent overlaid apoptotic stain (green) and nuclear stain (red), and arrows represent 
DNA fragmentation after treatment for 4 h. Photographed on a Fluorescence Olympus 
AX70 Microscope at 400× magnification. Scale bar = 50 µM.  
 Mar. Drugs 2012, 10  
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Figure 6. TUNEL staining of primary-derived reproductive human granulosa cells (HGC) 
(A 1–4) and KGN granulosa tumor cell line (A 5–8) after 4 h treatment with D. orbita 
fraction 2 containing 6-bromoisatin. The percentage of apoptotic cells after HGC (B) and 
KGN cells (C) after treatment with 6-bromoisatin for 4 h and 24 h. The positive control 
represents 1 µg/mL DNase I (C1 and 5), for compound with the 1% DMSO control   
(C2 and 6), 0.005 mg/mL (C3 and 7) and 0.05 mg/mL (C4 and 8) of 6-bromoisatin. Photo 
micrographs were taken of four random microscope fields, and the number of TUNEL 
positive nuclei were calculated as a fraction of the total number of PI stained nuclei in each 
image. The average of the four fields was then calculated and the results of (A) and (B) are 
the mean ± 1 SEM of 3 repeat assays (n = 3). Univariate analysis of variance with contrast 
(K Matrix) were conducted to determine the percentage of apoptotic cells from total cells 
induced by 6-bromoisatin against the 1% DMSO control shown as 0 concentration at 4 and 
24 h. Significant difference between each treatment and the 1% DMSO control at 4 and 
24 h shown as p < 0.01 (**) and p < 0.001 (***). (C) Pictures represent overlaid apoptotic 
stain (green) and nuclear stain (red), and arrows represent DNA fragmentation after 
treatment for 4 h. Photographed on a Fluorescence Olympus AX70 Microscope at 400× 
magnification. Scale bar = 50 µM. 
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In the presence of 0.05 mg/mL tyrindoleninone after 4 h treatment, 31% of HGC (Figure 5A,C) and 
66% of KGN cells were TUNEL positive (Figure 5B,C). After 24 h exposure to 20 µM (0.005 mg/mL) 
of tyrindoleninone only 16% of HGC were labelled, in comparison to 62% of KGN cells (p < 0.001; 
Figure 5A,B). DNA fragmentation after 4 h exposure to 10 tyrindoleninone in both HGC and KGN 
therefore occurred at a lower concentration (0.05 mg/mL) than that which caused LDH release 
(1953 µM or 0.5 mg/mL; Figure 2). 
When HGC and KGN cells were treated with 6-bromoisatin at 223 µM (0.05 mg/mL) for 4 h, 27% of 
primary HGC were TUNEL positive (Figure 6A,C), whereas 58% of KGN cells were positive   
(p < 0.001; Figure 6B,C), and after 24 h of treatment with 6-bromoisatin (22 µM or 0.005 mg/mL), 
10% of HGC were TUNEL labelled in comparison to a statistically significant increase in TUNEL 
positive KGN cells of 53% (p < 0.001; Figure 6A,B). In a similar manner to tyrindoleninone, when 
treated with 6-bromoisatin TUNEL fluorescence indicating DNA fragmentation was generally detected 
at lower concentrations than required to induce necrosis by LDH release (2232 µM or 0.5 mg/mL; 
Figure 4). 
The consensus is that apoptosis can be activated via two main pathways, the extrinsic (cell surface 
activation) or intrinsic (mitochondrial activation) pathways [44]. Apoptosis in the KGN and COV434 
human granulosa cancer cell lines treated with cisplatin was attributed to the extrinsic receptor 
pathway [49]. The extrinsic pathway via the Fas-Fas mediated ligand system was also implicated in 
KGN apoptosis when KGN cells exposed to interferon-γ underwent Fas-induced apoptosis [38]. 
Furthermore, the Fas-Fas pathway was involved in primary granulosa-luteal cell apoptosis [50]. 
TRAIL apoptosis via the intrinsic pathway has also been identified in primary granulosa and theca 
cells of the ovary, regulated by Bcl-212 proteins [51]. Therefore, it could be hypothesized that 
tyrindoleninone and 6-bromoisatin inhibited cell proliferation and activated apoptosis in the KGN 
granulosa cancer cell line via the TRAIL-induced or Fas-Fas pathways. Future studies, including 
investigation of initiator caspase 8 and 9, could help discriminate between the extrinsic and intrinsic 
pathway for the induction of apoptosis by these brominated indoles. 
At higher concentrations of tyrindoleninone and 6-bromoisatin (≥0.05 mg/mL) a dose dependent 
increase in LDH release was observed in the KGN cells, HGC, JAr and OVCAR-3 cells. Our   
caspase-3/7 and TUNEL results suggest that tyrindoleninone and 6-bromoisatin activate cell death  
by apoptosis at low concentrations, but cause secondary necrosis or necrosis at higher   
concentrations [42,52]. In other words, at higher concentrations the apoptotic pathway was terminated 
and secondary necrosis may have been triggered. Benkendorff et al. [30] have shown that a crude 
extract (0.5 mg/mL) from the egg masses of D. orbita induced both apoptosis and necrosis in the T-cell 
lymphoma, Jurkat cell line, and necrosis alone in the HT29, solid colon cancer cell line after a 4 h 
exposure [30]. The authors of that study pointed out that cell death by apoptosis in lymphoma cell lines 
is congruent with published studies, whereas necrosis is more common in solid tumour cell lines [30]. 
Interestingly, in vivo studies have demonstrated that crude D. orbita extracts successfully induced 
apoptosis in cells of the distal colon in response to genotoxic damage [32]. High concentrations of the 
D. orbita extracts (1 mg/mL) induced a significantly greater rate of apoptosis than low concentrations 
(0.125 mg/mL) in vivo [32]. This is likely to be related to in vivo degradation and metabolism of the 
active compounds, thus requiring higher concentrations for oral delivery than is necessary to induce an 
effect in vitro. The induction of apoptosis at lower concentrations in our study compared to previous Mar. Drugs 2012, 10  
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studies may also be related to testing the purified compounds rather than the crude extract in the 
apoptosis assays. Different concentrations of these muricid compounds possibly stimulate different  
cell death pathways in different cell lines and therefore in the KGN reproductive cells, apoptosis is 
being activated at low concentrations, whereas secondary necrosis or necrosis is activated at 
high concentrations. 
3. Experimental Section  
3.1. Extraction, Purification and Chemical Analysis 
All chemicals used in this research were HPLC grade and purchased from Sigma-Aldrich unless 
otherwise stated. Bioactive compounds were extracted from Dicathais orbita egg masses that were 
collected from re-circulating tanks at Flinders University, South Australia. The egg capsules (285 g) 
were cut open and soaked in chloroform and methanol (v/v) for 24 h. The chloroform layer was then 
separated from the aqueous layer, filtered to remove tissue residue and evaporated to dryness under 
vacuum pressure (474 mbar; 40 °C) on a Buchi Rotary evaporator, yielding 3.726 g of a brown/red oil. 
This extract was subjected to liquid chromatography (Waters, Milford, USA; 2695 Separation Module 
and 2487 dual wavelength UV detector) coupled to an electrospray ionization mass spectrometer (ESI; 
Micromass Quattro micro™), with UV detection at wavelengths 300 and 600 nm, and data was 
acquired by the Masslynx Software as previously described [30] The brown/red oil was stored at   
−20 °C under N2 gas in amber vials until semi-purified.  
To facilitate the separation of the bioactive compounds tyrindoleninone and 6-bromoisatin, the 
crude samples extracted from the egg masses were semi-purified using flash silica chromatography 
under N2 pressure using a solvent system with increasing polarity of dichloromethane (DCM), 5% 
methanol in DCM and 10% methanol in DCM (Fraction 1: 0.120 g eluted from the column with DCM 
and Fraction 2: 0.105 g eluted from the column with 5% DCM). The collected fractions were dried on 
a Buchi Rotary evaporator and stored under N2 at −20 °C in amber vials prior to cell culture assays. 
LC/MS analysis was performed to identify the bioactive compounds in the two semi-purified fractions.  
For cell assays, the D. orbita fractions were prepared fresh on the day of the experiment by 
dissolving in dimethyl sulfoxide (DMSO; 100%) at 100× the final concentration. These were diluted to 
a range of working concentrations (0.001–0.5 mg/mL) in complete cell assay medium to give a final 
working concentration per well of 1% DMSO. All samples were filtered through a 0.22 μM (Sartorius) 
filter before use. 
3.2. Cell Culture 
3.2.1. Isolation of Primary-Derived Human Granulosa Cells 
Primary-derived human reproductive granulosa cells (HCG) were isolated from the follicular 
aspirates donated by women (n = 3) undergoing assisted reproductive technology (ART) at Flinders 
Medical Centre, Adelaide, South Australia under a protocol approved by the Flinders Clinical Research 
Ethics Committee (260/067). Granulosa cells were donated by  women with normal reproductive 
physiology who were undergoing ART to treat male  infertility. Granulosa cell isolation has been Mar. Drugs 2012, 10  
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described previously [53]. Briefly, pooled aspirates for each woman were isolated by centrifugation at 
107× g for 10 min, followed by two cycles of rinsing and then the cell suspension was re-suspended in 
Dulbecco’s modified Eagle’s HAMS F12 (DMEM-F12; GIBCO, Invitrogen Corporation) medium 
supplemented with 10% FBS (GIBCO Invitrogen Corporation), penicillin/streptomycin 5000 IU/mL 
and 5000 μg/mL respectively (Thermo Scientific), insulin (5 μg/mL), transferin apohuman (5 μg/mL), 
selenium sodium selenite (5 ng/mL) buffered with 1.2 g/L NaHCO3 (Pfizer). Granulosa cells were 
separated from the red blood cells using a lymphoprep (Ficoll-Paque TMPlus) column. The purified 
granulosa cells were rinsed and re-suspended in DMEM/F12 complete medium. 
3.2.2. Cell Line Culture 
The KGN granulosa cell line [38] was maintained in the same DMEM/F12 complete media as the 
HCG. The JAr [40] and OVCAR-3 cell lines [39] obtained from the (Global Bioresource Centre™ 
American Tissue Culture Collection) were maintained in RPMI-1640 medium supplemented with   
10 and 20% FBS respectively (GIBCO, Invitrogen Corporation), sodium pyruvate (1 mM), HEPES  
(10 mM), glucose (4.5 g/L), L-glutamine (2 mM), and penicillin and streptomycin (5000 IU/mL and 
5000 μg/mL, respectively; Thermo Scientific). Insulin solution from bovine pancreas (0.01 mg/mL) 
was also added to OVCAR-3 medium and both JAr and OVCAR-3 medium was buffered with 1.5 g/L 
NaHCO3 (Pfizer). Cell lines were maintained in 75 cm
2 sterile tissue culture flasks (NUNC, Thermo 
Fisher Scientific) at 37 °C in a humidified atmosphere with 5% CO2 and sub-cultured every 2–3 days 
as required. When the cells were 80% confluent they were either passaged or used in experiments. 
Viable cell numbers were determined using the trypan blue exclusion assay on a haemocytometer [54]. 
3.3. Combined Caspase 3/7, Membrane Integrity and Cell Viability Assays  
The primary-derived granulosa cells, along with the KGN, JAr and OVCAR-3 cell lines   
(10,000 cells per well) were plated into sterile white (opaque) 96-well plates (Interpath) and clear 
sterile 96-well plates (Interpath) in 0.1 mL per well of complete cell culture medium  for 24 h 
(granulosa, KGN and OVCAR-3 cells) and 2 h (for JAr cells) to allow cell adherence. Standard curves 
of 0–40,000 cells per well (primary granulosa cells) and 0–80,000 cells per well (for KGN, JAr and 
OVCAR-3 cells) in six replicate wells were plated into clear 96-well plates, alongside the test plates. 
After the initial cell adherence period, spent media (media deficient of nutrients and serum) were 
discarded and primary-derived granulosa, KGN, JAr and OVCAR-3 cells were treated with the two  
D. orbita fractions at concentrations of 0.005, 0.01, 0.05, 0.1, and 0.5 mg/mL in a final volume of  
0.1 mL per well in triplicate wells, for 4 and 24 h at 37 °C + 5% CO2. 1 h prior to the end of each 
incubation period two positive controls were added; one for apoptosis (1 μg/mL DNase I), and the 
second for necrosis (2 μL per well of a cell lysis buffer; Promega). This experiment was repeated on 
three separate occasions (n = 3). 
3.3.1. LDH Membrane Integrity and Caspase-Glo 3/7 Assay  
After 4 and 24 h exposure to the D. orbita fractions in opaque 96-well plates, a combined membrane 
integrity and caspase 3/7 assay were performed on the primary-derived granulosa cells and KGN cells. Mar. Drugs 2012, 10  
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The CytoTox-ONE Homogeneous Membrane Integrity Assay kit (Promega) was applied according to 
the manufacturer’s instructions. After the fluorescence was read at 535EX/590EM, the Caspase-Glo 3/7
® 
assay (Promega) was applied to  the primary granulosa cells and KGN cells according to the 
manufacturer’s instructions for1h and the plates were read on full light to capture total luminescence. 
The LDH-membrane integrity assay alone was performed on the JAr and OVCAR-3 cells using the 
CytoTox-ONE Homogeneous Membrane Integrity Assay kit (Promega). This assay was repeated on 
three separate occasions (n = 3). 
3.3.2. Crystal Violet Cell Viability Assay 
After 4 and 24 h exposure to D. orbita fractions in clear 96-well plates, media and all dead 
unattached cells were removed. The remaining adherent cells were rinsed with sterile 1× PBS and the 
crystal violet assay was performed [55]. The crystal violet assay is a colourmetric assay in which only 
the nuclei of live cells take up the crystal violet stain (0.5%) [55]. The absorbance in the wells of the 
crystal violet plates were read on an automatic spectrophotometer at 570 nm, with reference absorbance 
630 nm using KC Junior Software. This assay was repeated on three separate occasions (n = 3). 
3.3.3. MTT Cell Viability Assay 
After 4, 24, 48 and 72 h exposure to D. orbita fractions in clear 96-well plates, media and all dead 
unattached cells were removed. The remaining adherent cells were rinsed with sterile 1× PBS and the 
MTT assay was performed. The MTT assay measures the reduction of a yellow substrate to formazan, 
a purple precipitate, by the mitochondrial succinate dehydrogenase enzymes [56]. A solution of   
0.5 mg/mL MTT (was added to wells in a final volume of 0.1 mL. The plates were then incubated for  
1 h (JAr cells) and 18 h (KGN, OVCAR-3 and GC cells) at 37 °C and 5% CO2. At the end of the 
incubation period, 80 μL/well 20% SDS in 0.02 M HCl was added and plate was incubated for a 
further 1 h at room temperature in the dark. The absorbance was the measured at 570 nm, with 
reference absorbance 630 nm, using an automatic spectrophotometer using KC Junior software. This 
assay was repeated on three separate occasions (n = 3). 
3.4. Detection of Apoptotic KGN and Primary-Derived Granulosa Cells by TUNEL 
Primary-derived human granulosa cells and KGN cells were plated into Nunc Lab-Tek II CC2 
Chamber Slides at 30,000 cells per chamber well in a final volume of 0.3 mL of DMEM/F12 + 10% FBS 
complete cell culture medium and incubated for 24 h at 37 °C + 5% CO2 to allow cell attachment to 
slides. Spent media (media deficient of nutrients and serum) and non-viable and non-adherent cells 
were discarded and replaced with the D. orbita fractions at concentrations of 0.005, 0.01 and   
0.05 mg/mL in a final volume of 0.3 mL of DMEM/F12 + 10% medium. A medium-only and a  
1% DMSO control were also added before incubation for 4 and 24 h at 37 °C + 5% CO2. This 
experiment was repeated on three separate occasions (n = 3). The supernatant was removed and the 
cells rinsed with PBS before fixation with 4% paraformaldehyde for 25 min at room temperature. The 
DeadEnd™ Fluorometric  TUNEL System (Promega) was performed as recommended by the 
manufacturer. Briefly the cells were treated with 0.2% Triton X-100 for 5 min, to permeablize the Mar. Drugs 2012, 10  
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cells. The cells were rinsed in PBS before the addition of 50 μL of rTdT incubation buffer (Promega) 
at 37 °C for 1 h, protected from light. Cells were rinsed in 2× sodium chloride and sodium citrate 
solution (Promega) for 15 min at room temperature (25 °C) then rinsed again with PBS. The cells were 
counter-stained with 1 μg/mL propidium iodide (PI). A separate positive control slide of 1 μg/mL 
DNase I, and a negative control slide of buffer without rTdT, was  prepared in conjunction with 
treatment slides. Cells were examined immediately and photographed at 200 and 400× magnification 
using a Fluorescence Olympus BX50 Microscope with filter Chroma 31001 at excitation 450–495 nm, 
Dichroic 505 and emission 515–555 nm for the green fluorescein of TUNEL and Chroma 31002 at 
excitation 515–550 nm, Dichroic 565 and emission 575–615 nm for the red fluorescence of the PI 
staining. Photomicrographs of four fields of view were taken for each treatment in each repeat of the 
assay and the number of TUNEL positive nuclei, stained bright green, were calculated as a fraction of 
the total number of PI stained nuclei, stained bright red, in each image. The average of the four fields 
was then calculated. 
3.5. Statistical Analysis 
All experiments were repeated on three independent occasions (n = 3) and the results are presented 
as mean ± 1 SEM. Two-way analyses of variance (ANOVA) using the sensitive contrast K Matrix 
analysis tests [57] were conducted to examine the effects of the semi-purified D. orbita fractions on 
caspase 3/7 activity, LDH release, cell viability and, to determine the number of apoptotic cells 
induced by the semi-purified D. orbita fractions using SPSS software package version 17. Homogeneity 
of variance was determined using the Levine’s Test of Equality of Error and the alpha value adjusted 
to <0.01 where homogeneity of variance was violated. 
4. Conclusion 
In conclusion, this study has identified the Australian marine mollusc Dicathais orbita as a source 
of potential anticancer agents with the potential to treat female reproductive cancers. The natural 
brominated muricid compounds tyrindoleninone and 6-bromoisatin selectively inhibit and kill 
reproductive cancer cell lines at low concentrations, while having minimal effect on primary-derived 
human granulosa cells. Furthermore, both tyrindoleninone and 6-bromoisatin induce cell death in the 
human granulosa cancer cell line KGN by apoptosis as opposed to necrosis at the lowest concentrations. 
Hence our data together with previous studies [30,32] suggests that these naturally occurring compounds 
are selective towards human cancer cell lines both in vitro and in vivo and thus are promising targets 
for the treatment of reproductive cancers. 
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